Multicenter Retrospective Study on Streptobacillus Moniliformis Infections in France (Streptobacil)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: François DANION, MD
- Phone Number: 33 3 69 55 15 88
- Email: francois.danion@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
-
Contact:
- François DANION, MD
- Phone Number: 33 3 69 55 15 88
- Email: francois.danion@chru-strasbourg.fr
-
Principal Investigator:
- François DANION, MD
-
Sub-Investigator:
- Frédéric SCHRAMM, MD
-
Principal Investigator:
- Amandine ROBERT, MD
-
Principal Investigator:
- GUILLOUZOUIC GUILLOUZOUIC, PharmD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Minor patient aged 1 to 17 years
- Adult patient ≥18 years
- Proven Streptobacillus moniliformis infection between 01/01/2007 and 31/12/2023
- Subject not objecting, after being informed, to the reuse of their data for the purposes of this research
- Holders of parental authority not objecting, after being informed, to the reuse of their data for the purposes of this research their child for the purposes of this research
Exclusion Criteria:
- Subject and/or holder of parental authority having expressed opposition to participating in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retrospective study of the effectiveness of antibiotic therapy initiated for the treatment of Streptobacillus moniliformis infection.
Time Frame: Negative blood culture 15 days after the start of antibiotic therapy.
|
Clinical cure 15 days after the start of antibiotic therapy.
This cure is based on a negative blood culture (absence of germs) performed 15 days after the start of treatment.
|
Negative blood culture 15 days after the start of antibiotic therapy.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9237
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.